NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$35.34
1.46 (4.31%)
▲
5d:
+16.21%
30d:
+35.2%
90d:
+63.16%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NGNE is 10.9% above its trading range ($31.88). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NGNE is 10.9% above its trading range ($31.88). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $35.34, which is considered extended relative to its 30-day fair value range of $27.18 to $31.88.
Technical Outlook: Technically, NGNE is in a strong uptrend. The price is approaching resistance at $35.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: NGNE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.00 (+129.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NGNE is in a strong uptrend. The price is approaching resistance at $35.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: NGNE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.00 (+129.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.18 -
$31.88
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price significantly overextended (+10.9% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 129.2% below Wall St target ($81.00)
- WARNING: Recommendation downgraded due to 10.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$27.18 -
$31.88
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.63
(15.9%)
Support & Resistance Levels
Support Level
$29.66
Resistance Level
$35.47
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.48
Wall Street Target
$81.00
(+129.2%)
Share & Embed Analysis
Last updated: July 02, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Mikail Cvijic
SELL
4045 shares
2026-03-13
Stuart Cobb
SELL
6797 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
